PCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) template
PGD template to support the national pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) vaccination programme.
Applies to England
Documents
Details
This patient group direction (PGD) template is to support the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV13 or PCV15) to individuals from 12 weeks to under 2 years of age in accordance with the national immunisation programme.
The PCV PGD version 5.00 is valid from 28 February 2024 to 31 May 2026.
Practitioners must not use this聽PGD聽template until it has been authorised in Section 2. This is a legal requirement (see聽. Practitioners should follow local policy/procedures to access authorised聽PGD听诲辞肠耻尘别苍迟蝉.
This PGD template should be used with reference to current national guidance, the Green Book, and for the vaccine.
Updates to this page
-
Added version 5.00 - see page 3 for change history.
-
Added version 04.00 - see change history on page 2.
-
Added V03.00: updated PGD for the PCV 1+1 routine schedule for infants born on or after 1 Jan 2020.
-
Added updated PGD template: validity from 6 weeks of age and addition of outbreak indication.
-
Added notice of extension for PCV (13-valent, adsorbed) patient group direction.
-
First published.